Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
#DiabetesCare #HealthcareInnovation #AIDSystems #Type1Diabetes #PublicHealth #HealthEquity #MedTech #AustralianHealthcare #ChronicDisease #PrimaryCare To view or add a comment, sign in Theres been a lot of noise around recent CMS updates on obesity medicationsand some of it has been off the mark
Yet somehow I thought I could white knuckle my way through it
Presented for research literature review only Joma M et al
4 Comparison of change from baseline by week for selected cardiometabolic endpoints for semaglutide versus placebo
Methodological limitations of existing research include: Observational study designs that cannot establish causationindividuals prescribed GLP-1 agonists may differ systematically from comparison groups Confounding variables such as concurrent lifestyle interventions, psychological support, or other medications Short follow-up periods that do not capture long-term outcomes or relapse patterns Publication bias , with positive findings more likely to be reported than null results Safety considerations are paramount
